ArticleFrontiers in immunology2026
Integrated analysis of isorhamnetin-associated targets in chronic pancreatitis and pancreatic cancer: immune-infiltration associations and antitumor effects in pancreatic cancer cells.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic pancreatitis (CP) creates an inflammatory pancreatic microenvironment and is an established risk factor for pancreatic cancer (PC). However, immune-inflammatory links between CP and PC remain unclear. Isorhamnetin (ISO), a natural flavonoid with anti-inflammatory and antitumor activities, may influence pancreatic inflammatory signaling. This study investigated ISO-associated molecular networks shared by CP and PC, examined the relationships between prioritized targets and transcriptome-estimated immune-cell infiltration, and evaluated the effects of ISO in pancreatic cancer cells. Methods: CP- and PC-associated targets were collected from disease databases, and ISO targets were obtained from drug-target prediction platforms. Disease- and ISO-related targets were analyzed using protein-protein interaction networks, functional enrichment, and hub-gene screening. The expression, prognostic relevance, diagnostic performance, and immune infiltration associations of hub genes were evaluated using TCGA-PAAD, GTEx, Kaplan-Meier Plotter, ROC analysis, and CIBERSORTx. Molecular docking and 100 ns molecular dynamics simulations assessed ISO-target binding stability. Two-sample Mendelian randomization (MR) explored potential causal associations between genetically proxied circulating levels of the six hub proteins and CP or PC risk. The effects of ISO on proliferation, wound closure, apoptosis, and target protein expression were examined in PANC-1 and BXPC-3 cells. Results: 372 overlapping CP- and PC-associated targets and 48 ISO-related targets were identified. EGFR, AKT1, MMP9, BCL2, TNF, and IL6 were screened as hub genes. Functional enrichment indicated targets were involved in inflammatory responses, cytokine-related signaling, apoptosis regulation, epithelial proliferation, pancreatic cancer-related pathways, and PI3K-Akt signaling. Hub-gene expression was correlated with CIBERSORTx-estimated immune-cell fractions, including activated natural killer cells and several T-cell subsets. Molecular docking and molecular dynamics simulations provided preliminary support for ISO-target interactions and complex stability. Across the 12 prespecified protein-outcome combinations, MMP9-CP was the only nominal IVW association. Conclusion: ISO may influence CP- and PC-associated molecular networks through multitarget regulation involving EGFR, AKT1, MMP9, BCL2, TNF, and IL6. These findings provide hypothesis-generating computational, genetic, and cellular evidence supporting investigation of ISO in pancreatic inflammation-associated tumor biology. However, immune regulatory effects, MMP9/IL6 protein modulation, and EGFR/AKT pathway activation require further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.